نتائج البحث - Fabio Frediani

  • يعرض 1 - 7 نتائج من 7
تنقيح النتائج
  1. 1
    Improvement in Quality of Life and Activity Limitations in Migraine Patients after Prophylaxis. A Prospective Longitudinal Multicentre Study

    Improvement in Quality of Life and Activity Limitations in Migraine Patients after Prophylaxis. A Prospective Longitudinal Multicentre Study حسب Domenico D’Amico, Alessandra Solari, Susanna Usai, Patrizia Santoro, P. Bernardoni, Fabio Frediani, Riccardo De Marco, N Massetto, Gennaro Bussone

    منشور في 2005
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Current and emerging evidence-based treatment options in chronic migraine: a narrative review

    Current and emerging evidence-based treatment options in chronic migraine: a narrative review حسب Elio Clemente Agostoni, Piero Barbanti, Paolo Calabresi, Bruno Colombo, Pietro Cortelli, Fabio Frediani, Pietrangelo Geppetti, Licia Grazzi, Massimo Leone, Paolo Martelletti, Luigi Alberto Pini, Maria Pia Prudenzano, Paola Sarchielli, Gioacchino Tedeschi, Antonio Russo

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Applications of Ketogenic Diets in Patients with Headache: Clinical Recommendations

    Applications of Ketogenic Diets in Patients with Headache: Clinical Recommendations حسب Cherubino Di Lorenzo, Giovanna Ballerini, Piero Barbanti, Andrea Bernardini, Giacomo D’Arrigo, Gabriella Egeo, Fabio Frediani, Riccardo Garbo, Giulia Pierangeli, Maria Pia Prudenzano, Nicoletta Rebaudengo, Grazia Semeraro, Giulio Sirianni, Mariarosaria Valente, Gianluca Coppola, Mackenzie C. Cervenka, Giovanni Spera

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients

    Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients حسب Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Claudia Altamura, Florindo d’Onofrio, Cinzia Finocchi, Maria Albanese, Marco Aguggia, Renata Rao, Maurizio Zucco, Fabio Frediani, Massimo Filippi, Roberta Messina, Sabina Cevoli, Antonio Carnevale, Giulia Fiorentini, Stefano Messina, Francesco Bono, Paola Torelli, Stefania Proietti, Stefano Bonassi, Fabrizio Vernieri

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study

    Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study حسب Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, Stefania Proietti, Florindo d’Onofrio, Paola Torelli, Marco Aguggia, Davide Bertuzzo, Cinzia Finocchi, Michele Trimboli, Sabina Cevoli, Giulia Fiorentini, Bianca Orlando, Maurizio Zucco, Laura Di Clemente, Ilaria Cetta, Bruno Colombo, Monica Laura Bandettini di Poggio, Valentina Favoni, Licia Grazzi, Antonio Salerno, Antonio Carnevale, Micaela Robotti, Fabio Frediani, Claudia Altamura, Massimo Filippi, Fabrizio Vernieri, Stefano Bonassi

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Late Response to Anti-CGRP Monoclonal Antibodies in Migraine

    Late Response to Anti-CGRP Monoclonal Antibodies in Migraine حسب Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, Paola Torelli, Stefania Proietti, Sabina Cevoli, Stefano Bonassi, Giulia Fiorentini Psy, Roberta Messina, Bruno Colombo, Florindo d’Onofrio, Maria Albanese, Cinzia Finocchi, Antonio Salerno, B. Mercuri, Antonio Carnevale, Francesco Bono, Fabio Frediani, Licia Grazzi, Domenico D’Amico, Massimo Filippi, Claudia Altamura, Fabrizio Vernieri, Marco Aguggia, Davide Bertuzzo, Maurizio Zucco, Laura Di Clemente, Michele Trimboli, Valentina Favoni, Paola Di Fiore

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study

    Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study حسب Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Paola Torelli, Cinzia Finocchi, Florindo d’Onofrio, Luigi d’Onofrio, Renata Rao, Stefano Messina, Laura Di Clemente, Angelo Ranieri, Massimo Autunno, Giuliano Sette, Bruno Colombo, Antonio Carnevale, Marco Aguggia, Miriam Tasillo, Francesco Zoroddu, Fabio Frediani, Massimo Filippi, Carlo Tomino, Stefania Proietti, Stefano Bonassi, Maria Albanese, Marco Bertolini, Davide Bertuzzo, Maria Bloise, Francesco Bono, L. Borrello, Cecilia Camarda, Giulia Fiorentini, Licia Grazzi, Domenica Le Pera, Roberta Messina, Pietro Querzani, Antonio Salerno, Silvia Strumia, Alessandro Valenza, Fabrizio Vernieri, Giovanna Viticchi

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: